Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

ANGLE plc

Healthcare US ANPCF

0.0199USD
0.00(0%)

Last update at 2026-06-03T20:00:00Z

Day Range

0.010.01
LowHigh

52 Week Range

0.010.31
LowHigh

Fundamentals

  • Previous Close 0.02
  • Market Cap20.05M
  • Volume20000
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-15.54900M
  • Revenue TTM2.62M
  • Revenue Per Share TTM0.008
  • Gross Profit TTM 0.82M
  • Diluted EPS TTM-0.06

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2023-04-30 2022-12-31 2022-04-30
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2023-04-30 2022-12-31 2022-04-30
Income before tax -15.02900M -21.63200M -24.43900M -24.43900M -17.36300M
Minority interest - - - - -
Net income -14.22500M -20.13200M -21.68600M -21.68600M -15.01200M
Selling general administrative 0.46M 0.38M 0.56M 0.56M 0.34M
Selling and marketing expenses - - - - -
Gross profit 1.78M 1.53M 0.61M 0.61M 0.71M
Reconciled depreciation 1.70M 2.31M 2.84M 2.84M 1.49M
Ebit - - -24.07100M -24.07100M -17.20600M
Ebitda - - -21.23300M -21.23300M -15.71900M
Depreciation and amortization - - 2.84M 2.84M 1.49M
Non operating income net other - - - - -
Operating income -15.47400M -20.45800M -24.20700M -24.20700M -17.23500M
Other operating expenses - - 25.25M 25.25M 18.25M
Interest expense 0.31M 0.33M 0.37M 0.37M 0.16M
Tax provision -0.80400M -1.50000M -2.75300M -2.75300M -2.35100M
Interest income 0.40M 0.46M 0.14M 0.14M 0.03M
Net interest income 0.09M 0.14M -0.23200M -0.23200M -0.12800M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - -2.75300M -2.75300M -2.35100M
Total revenue 2.86M 2.19M 1.04M 1.04M 1.01M
Total operating expenses 18.34M 22.64M 24.82M 24.82M 17.95M
Cost of revenue 1.08M 0.66M 0.43M 0.43M 0.30M
Total other income expense net - - -0.23200M -0.23200M -0.12800M
Discontinued operations - - - - -
Net income from continuing ops -14.22500M -20.13200M -21.68600M -21.68600M -15.01200M
Net income applicable to common shares - - -21.68600M -21.68600M -15.01200M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2023-04-30 2022-12-31 2022-04-30
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2023-04-30 2022-12-31 2022-04-30
Total assets 25.46M 31.18M 49.87M 49.87M 47.31M
Intangible assets 0.44M 0.53M 0.56M 0.56M 1.37M
Earning assets - - - - -
Other current assets - - - - -
Total liab 7.02M 8.24M 9.80M 9.80M 6.99M
Total stockholder equity 18.44M 22.94M 40.06M 40.06M 40.33M
Deferred long term liab - - 0.03M 0.03M 0.04M
Other current liab - - 0.61M 0.61M 1.04M
Common stock - - 26.06M 26.06M 23.51M
Capital stock 32.26M 26.06M 26.06M 26.06M 23.51M
Retained earnings -133.14500M -122.32800M -103.70200M -103.70200M -83.80800M
Other liab - - 0.22M 0.22M 0.26M
Good will 2.21M 2.21M 2.21M 2.21M 2.21M
Other assets - - 0.03M 0.03M 0.04M
Cash 10.43M 16.22M 31.90M 31.90M 31.84M
Cash and equivalents - - - - -
Total current liabilities 3.26M 3.94M 5.25M 5.25M 4.91M
Current deferred revenue - - - - -
Net debt - - -26.89500M -26.89500M -29.50100M
Short term debt - - 0.66M 0.66M 0.52M
Short long term debt - - - - -
Short long term debt total - - 5.00M 5.00M 2.34M
Other stockholder equity - - 117.71M 117.71M 100.62M
Property plant equipment - - 8.48M 8.48M 4.38M
Total current assets 16.41M 21.22M 38.63M 38.63M 39.37M
Long term investments - - - - -
Net tangible assets - - 37.33M 37.33M 36.80M
Short term investments - - - - -
Net receivables 0.77M 0.73M 1.80M 1.80M 5.17M
Long term debt - - - - -
Inventory 1.58M 1.68M 2.06M 2.06M 1.75M
Accounts payable 0.69M 1.06M 3.98M 3.98M 4.39M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 9.05M 9.97M 11.24M 11.24M 7.95M
Capital lease obligations 4.21M 4.55M 5.00M 5.00M 2.34M
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2023-04-30 2022-12-31 2022-04-30
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2023-04-30 2022-12-31 2022-04-30
Investments -0.04800M -0.20100M -1.75100M -1.75100M 16.54M
Change to liabilities - - -0.97800M -0.97800M 1.42M
Total cashflows from investing activities - - -1.75100M -1.75100M 14.77M
Net borrowings - - -0.81400M -0.81400M -0.61400M
Total cash from financing activities - - 18.10M 18.10M 18.99M
Change to operating activities - - 0.59M 0.59M 0.59M
Net income -14.22500M -20.13200M -24.43900M -24.43900M -17.36300M
Change in cash -5.82800M -15.78600M 0.06M 0.06M 19.76M
Begin period cash flow 16.22M 31.90M 31.84M 31.84M 12.08M
End period cash flow 10.43M 16.22M 31.90M 31.90M 31.84M
Total cash from operating activities -13.44800M -14.45800M -16.05000M -16.05000M -14.01000M
Issuance of capital stock 8.63M 0.01M 19.05M 19.05M 19.69M
Depreciation 1.70M 2.31M 2.84M 2.84M 1.49M
Other cashflows from investing activities - - 0.14M 0.14M 0.02M
Dividends paid - - - - -
Change to inventory 0.15M 0.09M -0.58000M -0.58000M -1.01500M
Change to account receivables - - -0.65000M -0.65000M 0.20M
Sale purchase of stock - - - - -
Other cashflows from financing activities - - -0.94900M -0.94900M -0.69900M
Change to netincome - - 5.20M 5.20M -1.07000M
Capital expenditures 0.44M 0.66M 1.89M 1.89M 1.79M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -1.13200M -1.03100M -1.61400M -1.61400M 0.61M
Stock based compensation 1.45M 1.89M 4.39M 4.39M 1.32M
Other non cash items -0.06700M -0.12700M 2.78M 2.78M -0.06500M
Free cash flow -13.89200M -15.11800M -17.93700M -17.93700M -15.79800M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ANPCF
ANGLE plc		 - -% 0.02 - - 7.64 1.27 6.62 -1.9987
TMO
Thermo Fisher Scientific Inc		 13.90 2.93% 487.85 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 9.45 5.31% 187.53 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc		 3.14 2.29% 140.54 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc		 5.33 0.95% 566.06 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

View All

Profile

CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and CellKeep Slide, a CTC harvesting technology. In addition, the company offers laboratory services, including CTC enrichment and liquid biopsy analysis services; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays. CelLBxHealth plc has a strategic partnership with BioView Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer; and agreement with NuProbe USA, Inc. to use pan-cancer next generation sequencing (NGS) panel. The company was formerly known as ANGLE plc and changed its name to CelLBxHealth plc in October 2025. CelLBxHealth plc was founded in 1994 and is based in Guildford, the United Kingdom.

ANGLE plc

Surrey Research Park, Guildford, United Kingdom, GU2 7AF

Key Executives

Name Title Year Born
Mr. Andrew David William Newland Founder, CEO & Exec. Director 1962
Mr. Ian Francis Griffiths CFO, Fin. Director, Company Sec. & Exec. Director 1965
Mr. Martin Cooke Director of Operations & Regulatory Affairs 1969
Mr. Andrew John Holder Head of Investor Relations 1968
Mr. Paul Smith Chief Commercial Officer NA
Dr. Madeline Repollet Head of Clinical Laboratories NA
Ms. Anne-Sophie Pailhes-Jimenez Head of R&D - ANGLE Europe Ltd. NA
Mr. Michael O'Brien Bus. Devel. Director NA
Mr. Peter Michael Collins CEO & Director 1958
Ms. Sinéad Eithne Armstrong Finance Director & Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.